Immunotherapies targeting CD38 in Multiple Myeloma
Open Access
- 5 August 2016
- journal article
- review article
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (11) , e1217374
Abstract
Recently, the monoclonal antibody daratumumab was approved as a single agent for the treatment of patients with relapsed/refractory Multiple Myeloma (MM). Daratumumab is an antibody targeting surface molecule CD38 on myeloma cells and the agent is already widely being used based on its good tolerability and proven efficacy. We believe, however, that the efficacy of this drug and other anti-CD38 monoclonal antibodies can be further improved by combining it with other types of immunotherapies. Furthermore, surface molecule CD38 can be used as a target for immunotherapies other than just naked monoclonal antibodies. In this report, we review the expression pattern of CD38 among normal tissues and in different types of plasma cell dyscrasias including their progenitor cells, minimal residual disease, and circulating tumor cells. We summarize the physiological role of CD38 as well as its role in the pathophysiology of MM and we present the most recent clinical trials using CD38 as a target. In addition, we highlight possible combination immunotherapies incorporating anti-CD38 monoclonal antibodies and we demonstrate alternative immunotherapeutic approaches targeting the same antigen such as CD38-specific chimeric antigen receptor (CAR) T cells.Keywords
This publication has 123 references indexed in Scilit:
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myelomaLeukemia, 2012
- T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1Blood Cancer Journal, 2012
- Circulating plasma cells predict the outcome of relapsed or refractory multiple myelomaLeukemia & Lymphoma, 2012
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cellsBlood, 2012
- Autologous Stem Cell Transplantation and Multiple Myeloma Cancer Stem CellsTransplantation and Cellular Therapy, 2012
- T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cellsLeukemia, 2011
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1Journal of Clinical Oncology, 2011
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Immunophenotypic studies of monoclonal gammopathy of undetermined significanceBMC Clinical Pathology, 2008
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBlood, 2008